{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:07:45Z","timestamp":1774490865203,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00467-024-06418-1","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T05:01:58Z","timestamp":1726722118000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["IgG-immunoadsorptions and eculizumab combination in STEC-hemolytic and uremic syndrome pediatric patients with neurological involvement"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0603-1970","authenticated-orcid":false,"given":"Charlotte","family":"Duneton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4995-2059","authenticated-orcid":false,"given":"Theresa","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-2879","authenticated-orcid":false,"given":"Claire","family":"Dossier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0242-1936","authenticated-orcid":false,"given":"Veronique","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-7100","authenticated-orcid":false,"given":"Marc","family":"Fila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6304-1481","authenticated-orcid":false,"given":"Patricia","family":"Mariani-Kurkdijan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-5070","authenticated-orcid":false,"given":"Isabelle","family":"Nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1359","authenticated-orcid":false,"given":"Olivia","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-9417","authenticated-orcid":false,"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"6418_CR1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/infdis\/151.5.775","volume":"151","author":"MA Karmali","year":"1985","unstructured":"Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775\u2013782","journal-title":"J Infect Dis"},{"key":"6418_CR2","first-page":"1073","volume":"365","author":"PI Tarr","year":"2005","unstructured":"Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073\u20131086","journal-title":"Lancet"},{"key":"6418_CR3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0031-3955(16)40096-9","volume":"42","author":"RL Siegler","year":"1995","unstructured":"Siegler RL (1995) The hemolytic uremic syndrome. Pediatr Clin North Am 42:1505\u20131529","journal-title":"Pediatr Clin North Am"},{"key":"6418_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ana.410190120","volume":"19","author":"KJ Sheth","year":"1986","unstructured":"Sheth KJ, Swick HM, Haworth N (1986) Neurological involvement in hemolytic-uremic syndrome. Ann Neurol 19:90\u201393","journal-title":"Ann Neurol"},{"key":"6418_CR5","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1542\/peds.2005-0785","volume":"117","author":"RS Oakes","year":"2006","unstructured":"Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117:1656\u20131662","journal-title":"Pediatrics"},{"key":"6418_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/cid\/cis196","volume":"54","author":"A Rosales","year":"2012","unstructured":"Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-H\u00f6ller D, W\u00fcrzner R, Karch H, German-Austrian HUS Study Group (2012) Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 54:1413\u20131421","journal-title":"Clin Infect Dis"},{"key":"6418_CR7","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","volume":"28","author":"JM Spinale","year":"2013","unstructured":"Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28:2097\u20132105","journal-title":"Pediatr Nephrol"},{"key":"6418_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00467-018-4131-z","volume":"34","author":"C Monet-Didailler","year":"2019","unstructured":"Monet-Didailler C, Godron-Dubrasquet A, Madden I, Delmas Y, Llanas B, Harambat J (2019) Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort. Pediatr Nephrol 34:657\u2013662","journal-title":"Pediatr Nephrol"},{"key":"6418_CR9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, N\u00fcrnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"6418_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073","journal-title":"Kidney Int"},{"key":"6418_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Prov\u00f4t F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84\u201393","journal-title":"Am J Kidney Dis"},{"key":"6418_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"6418_CR13","first-page":"168","volume":"13","author":"L Monnens","year":"1980","unstructured":"Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P (1980) The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 13:168\u2013171","journal-title":"Clin Nephrol"},{"key":"6418_CR14","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2215\/CJN.02730409","volume":"4","author":"JM Thurman","year":"2009","unstructured":"Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1920\u20131924","journal-title":"Clin J Am Soc Nephrol"},{"key":"6418_CR15","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","volume":"182","author":"D Orth","year":"2009","unstructured":"Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, W\u00fcrzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394\u20136400","journal-title":"J Immunol"},{"key":"6418_CR16","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","volume":"117","author":"AL St\u00e5hl","year":"2011","unstructured":"St\u00e5hl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503\u20135513","journal-title":"Blood"},{"key":"6418_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/jimmunol.1100491","volume":"187","author":"M Morigi","year":"2011","unstructured":"Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187:172\u2013180","journal-title":"J Immunol"},{"key":"6418_CR18","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/ndt\/gfw078","volume":"31","author":"T Ahlenstiel-Grunow","year":"2016","unstructured":"Ahlenstiel-Grunow T, Hachmeister S, Bange FC et al (2016) Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 31:1114\u20131121","journal-title":"Nephrol Dial Transplant"},{"key":"6418_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21767\/2472-5056.100011","volume":"1","author":"TM Brady","year":"2016","unstructured":"Brady TM, Pruette C, Loeffler LF, Weidemann D, Strouse JJ, Gavriilaki E, Brodsky RA (2016) Typical HUS: evidence of acute phase complement activation from a daycare outbreak. J Clin Exp Nephrol 1:11","journal-title":"J Clin Exp Nephrol"},{"key":"6418_CR20","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00431-018-3255-2","volume":"177","author":"L Karnisova","year":"2018","unstructured":"Karnisova L, Hradsky O, Blahova K et al (2018) Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr 177:1837\u20131844","journal-title":"Eur J Pediatr"},{"key":"6418_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12601","volume":"181","author":"JR Ferraris","year":"2015","unstructured":"Ferraris JR, Ferraris V, Acquier AB et al (2015) Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 181:118\u2013125","journal-title":"Clin Exp Immunol"},{"key":"6418_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fmed.2020.00357","volume":"7","author":"GS Netti","year":"2020","unstructured":"Netti GS, Santangelo L, Paulucci L et al (2020) Low C3 serum levels predict severe forms of STEC-HUS with neurologic involvement. Front Med (Lausanne) 7:357","journal-title":"Front Med (Lausanne)"},{"key":"6418_CR23","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561\u20132563","journal-title":"N Engl J Med"},{"key":"6418_CR24","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","volume":"27","author":"JT Kielstein","year":"2012","unstructured":"Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, N\u00fcrnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R, Collaborators of the DGfN STEC-HUS registry (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807\u20133815","journal-title":"Nephrol Dial Transplant"},{"key":"6418_CR25","doi-asserted-by":"publisher","first-page":"e4565","DOI":"10.1136\/bmj.e4565","volume":"345","author":"J Menne","year":"2012","unstructured":"Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenm\u00fcller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, M\u00fcnte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Sch\u00f6cklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellh\u00f6ner P, Wiesner M, Zeissig S, B\u00fcning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565","journal-title":"BMJ"},{"key":"6418_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","volume":"34","author":"PR Walsh","year":"2019","unstructured":"Walsh PR, Johnson S (2019) Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 34:1485\u20131492","journal-title":"Pediatr Nephrol"},{"key":"6418_CR27","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/cid\/cix218","volume":"64","author":"S Loos","year":"2017","unstructured":"Loos S, Aulbert W, Hoppe B et al (2017) Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4. Clin Infect Dis 64:1637\u20131643","journal-title":"Clin Infect Dis"},{"key":"6418_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/cid\/cis531","volume":"55","author":"S Loos","year":"2012","unstructured":"Loos S, Ahlenstiel T, Kranz B et al (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753\u2013759","journal-title":"Clin Infect Dis"},{"key":"6418_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/ndt\/gft470","volume":"29","author":"Y Delmas","year":"2014","unstructured":"Delmas Y, Vendrely B, Clouzeau B et al (2014) Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 29:565\u2013572","journal-title":"Nephrol Dial Transplant"},{"key":"6418_CR30","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/ndt\/gfz158","volume":"35","author":"C Monet-Didailler","year":"2020","unstructured":"Monet-Didailler C, Chevallier A, Godron-Dubrasquet A et al (2020) Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 35:2147\u20132153","journal-title":"Nephrol Dial Transplant"},{"key":"6418_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00431-017-3077-7","volume":"177","author":"W Keenswijk","year":"2018","unstructured":"Keenswijk W, Raes A, Vande Walle J (2018) Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 177:311\u2013318","journal-title":"Eur J Pediatr"},{"key":"6418_CR32","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","volume":"34","author":"A Garnier","year":"2023","unstructured":"Garnier A, Brochard K, Kwon T et al (2023) Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial. J Am Soc Nephrol 34:1561\u20131573","journal-title":"J Am Soc Nephrol"},{"key":"6418_CR33","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","volume":"365","author":"C Frank","year":"2011","unstructured":"Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, M\u00fcller L, King LA, Rosner B, Buchholz U, Stark K, Krause G, HUS Investigation Team (2011) Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 365:1771\u20131780","journal-title":"N Engl J Med"},{"key":"6418_CR34","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","volume":"378","author":"A Greinacher","year":"2011","unstructured":"Greinacher A, Friesecke S, Abel P et al (2011) Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 378:1166\u20131173","journal-title":"Lancet"},{"key":"6418_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(12)60228-1","volume":"379","author":"C Combe","year":"2012","unstructured":"Combe C, Bui HN, de Pr\u00e9cigout V, Hilbert G, Delmas Y (2012) Immunoadsorption in patients with haemolytic uraemic syndrome. Lancet 379:517\u2013518 (author reply 518-519)","journal-title":"Lancet"},{"key":"6418_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/0961203310389487","volume":"20","author":"GH Stummvoll","year":"2011","unstructured":"Stummvoll GH (2011) Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus 20:115\u2013119","journal-title":"Lupus"},{"key":"6418_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1567-5688(09)71827-6","volume":"10","author":"R Klingel","year":"2009","unstructured":"Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives. Atheroscler Suppl 10:129\u2013132","journal-title":"Atheroscler Suppl"},{"key":"6418_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ckj\/sfs090","volume":"5","author":"C Pietrement","year":"2012","unstructured":"Pietrement C, Bednarek N, Baudouin V, Fila M, Desch\u00eanes G (2012) Immunoadsorption for paediatric post-diarrhoea haemolytic-uraemic syndrome with severe neurological involvement. Clin Kidney J 5:484\u2013485","journal-title":"Clin Kidney J"},{"key":"6418_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"6418_CR40","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2015","unstructured":"Pape L, Hartmann H, Bange FC et al (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94:e1000","journal-title":"Medicine (Baltimore)"},{"key":"6418_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0009922814534520","volume":"54","author":"A Saini","year":"2015","unstructured":"Saini A, Emke AR, Silva MC, Perlman SJ (2015) Response to eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations. Clin Pediatr (Phila) 54:387\u2013389","journal-title":"Clin Pediatr (Phila)"},{"key":"6418_CR42","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/dmcn.12161","volume":"55","author":"C Gitiaux","year":"2013","unstructured":"Gitiaux C, Krug P, Grevent D et al (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55:758\u2013765","journal-title":"Dev Med Child Neurol"},{"key":"6418_CR43","first-page":"246","volume":"55","author":"Z Ekinci","year":"2013","unstructured":"Ekinci Z, Candan C, Alpay H et al (2013) Hemolytic uremic syndrome outbreak in Turkey in 2011. Turk J Pediatr 55:246\u2013252","journal-title":"Turk J Pediatr"},{"key":"6418_CR44","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2215\/CJN.08921209","volume":"5","author":"S Nathanson","year":"2010","unstructured":"Nathanson S, Kwon T, Elmaleh M et al (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218\u20131228","journal-title":"Clin J Am Soc Nephrol"},{"key":"6418_CR45","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00467-008-0935-6","volume":"23","author":"J Scheiring","year":"2008","unstructured":"Scheiring J, Andreoli SP, Zimmerhackl LB (2008) Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 23:1749\u20131760","journal-title":"Pediatr Nephrol"},{"key":"6418_CR46","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0272-6386(12)70316-5","volume":"22","author":"A Gianviti","year":"1993","unstructured":"Gianviti A, Perna A, Caringella A, Edefonti A, Penza R, Remuzzi G, Rizzoni G (1993) Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis 22:264\u2013266","journal-title":"Am J Kidney Dis"},{"key":"6418_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00467-014-2918-0","volume":"30","author":"G Ardissino","year":"2015","unstructured":"Ardissino G, Dacc\u00f2 V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 30:345\u2013352","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06418-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06418-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06418-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T18:03:21Z","timestamp":1734977001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06418-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6418"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06418-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no confict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Robert Debr\u00e9 University Hospital, Paris, France. All methods were conducted in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}